Insider Selling: Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) CEO Sells 21,275 Shares of Stock

Mind Medicine (MindMed) Inc. (NASDAQ:MNMDGet Rating) CEO Robert Barrow sold 21,275 shares of the company’s stock in a transaction dated Thursday, June 16th. The stock was sold at an average price of 0.70, for a total transaction of 14,892.50. Following the completion of the sale, the chief executive officer now owns 3,955,619 shares in the company, valued at approximately 2,768,933.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Robert Barrow also recently made the following trade(s):

  • On Wednesday, May 25th, Robert Barrow sold 18,415 shares of Mind Medicine (MindMed) stock. The stock was sold at an average price of 0.77, for a total transaction of 14,179.55.

Shares of NASDAQ MNMD traded up 0.01 during midday trading on Tuesday, hitting 0.71. The stock had a trading volume of 2,901,583 shares, compared to its average volume of 3,590,417. The business’s 50 day moving average is 0.84 and its 200-day moving average is 1.11. The company has a market cap of $301.58 million, a P/E ratio of -3.09 and a beta of 1.16. Mind Medicine has a 52 week low of 0.70 and a 52 week high of 3.92.

Mind Medicine (MindMed) (NASDAQ:MNMDGet Rating) last issued its earnings results on Monday, March 28th. The company reported -0.04 earnings per share (EPS) for the quarter. Sell-side analysts expect that Mind Medicine will post -0.19 earnings per share for the current fiscal year.

A number of equities research analysts have weighed in on MNMD shares. Roth Capital started coverage on shares of Mind Medicine (MindMed) in a report on Wednesday, May 4th. They issued a “buy” rating and a $7.00 price objective on the stock. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Mind Medicine (MindMed) in a report on Monday, May 23rd.

Hedge funds and other institutional investors have recently modified their holdings of the company. Cetera Advisors LLC bought a new position in Mind Medicine (MindMed) during the third quarter valued at approximately $26,000. Squarepoint Ops LLC bought a new position in Mind Medicine (MindMed) during the third quarter valued at approximately $27,000. CWM LLC bought a new position in Mind Medicine (MindMed) during the fourth quarter valued at approximately $27,000. Fisher Asset Management LLC bought a new position in Mind Medicine (MindMed) during the fourth quarter valued at approximately $28,000. Finally, Virtu Financial LLC bought a new position in Mind Medicine (MindMed) during the first quarter valued at approximately $29,000. Hedge funds and other institutional investors own 12.40% of the company’s stock.

Mind Medicine (MindMed) Company Profile (Get Rating)

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal.

Featured Articles

Want More Great Investing Ideas?

Receive News & Ratings for Mind Medicine (MindMed) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mind Medicine (MindMed) and related companies with MarketBeat.com's FREE daily email newsletter.